Arrowhead Pharmaceuticals initiates study of ARO-C3
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
The insights collected by the app will support the pharmaceutical industry’s efforts to further improve patients’ lives by providing actionable data on patients’ individual experiences
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Resolv ER may remedy leading causes of blindness in adults
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Vonage Communications APIs allow developers to easily enhance and build intelligent, intuitive customer experiences directly into their existing applications and devices
Subscribe To Our Newsletter & Stay Updated